INVEST IN FISHER WALLACE LABORATORIES TODAY!
Neurostimulation Technology For Treating Depression
$37,647.16 Raised
REASONS TO INVEST
The company has sold over 100,000 units of its Version 1.0 device (over $40M in lifetime revenue) and is nearing completion of its Version 2.0 device that will inherit any newly obtained FDA Approval.
The company recently submitted the results of a clinical trial to the FDA to obtain FDA Approval for the treatment of Major Depressive Disorder and expects an approval decision in Q3 2023.
You may obtain the company's Version 2.0 device for free with an investment of $1500+ in this campaign.
Overview
On a mission to launch an FDA Approved wearable to treat depression
*OAK (Version 2) is currently under development and not yet available on the market.
Fisher Wallace has developed wearable brain stimulation technology that electrically stimulates the brain to treat depression, anxiety and insomnia without causing serious side effects. The company’s proof-of-concept device, the Fisher Wallace Stimulator®, has been cleared by the FDA and purchased by over 100,000 patients.
In 2022, the company completed a pivotal clinical trial and submitted it to the FDA to obtain FDA Approval for the treatment of Major Depressive Disorder. The rapidity of treatment and the Week 4 responder rate achieved in the trial is comparable to the drug esketamine and caused no serious adverse events. The company expects to receive an approval or denial decision from the FDA by Q3 2023. Approval will support the company’s efforts to scale the business and obtain insurance reimbursement for its products.
The company also launched a first responder pilot program in collaboration with the Seattle Police Department and Washington State University in 2022 to improve the mental health and wellness of uniformed officers and 911 responders. Other departments have since joined the program, and enrollment remains open. The results of this program are intended to support the company’s efforts to scale its solution to first responder communities nationwide.
Since the outbreak of COVID-19, professional sports journalism has focused on the mental health crisis affecting professional athletes, and in October 2022, the company engaged sports agent David Sloane to assist in increasing adoption of the company’s technology by pro sports teams, with a focus on Major League Baseball and the NFL.
The company is nearing completion of its Version 2.0 device, called OAK, in collaboration with Alloy Product Development and Eric Fields, the engineers and designers behind Beats, Nest and the Microsoft Hololens. OAK will deliver the same treatment as the company’s Version 1.0 device and will inherit any new regulatory approvals or clearances.
With world-class design and scientific validation, OAK is intended to appeal to tens of millions of people seeking a better way to improve mental health and wellness.
THE PROBLEM
We believe delayed treatment effects, side effects, modest efficacy, and high administrative costs make drug therapy and behavioral therapy insufficient solutions
Antidepressant medication can take as long as 12 weeks to be effective (source). Medication also causes a wide range of side effects, sometimes serious, and even in generic form is expensive when the cost of doctor visits is included. The average cost of seeing a therapist is $100 - $200 per session (source) and as many as half of all patients fail to complete the “homework” associated with cognitive behavioral therapy that’s needed to experience results (source). While these standards of care help millions of patients every year, millions more are in need of safe, effective alternatives or adjuncts.
THE SOLUTION
Rapid treatment with minimal side effects
Our clinical trial evidence demonstrates that our technology rapidly treats depression, as well as anxiety and insomnia (often co-occuring symptoms with depression), without causing serious side effects. The device may be used safely as a standalone treatment or in conjunction with medication and/or psychotherapy. Additionally, more than 40.1% of surveyed Fisher Wallace customers report improvements in cognitive performance (focus, concentration, memory) in addition to symptom reduction. 77.4% of surveyed customers stated an intention to use their Fisher Wallace device for the rest of their lives to maintain mental health and cognitive performance.
*OAK (Version 2) is currently under development and not yet available on the market.
OUR TRACTION
Proven product-market fit and scalability
Leveraging a vertically integrated e-commerce model with an integrated telemedicine prescription process, Fisher Wallace has succeeded in generating over $40 million in lifetime revenue from its direct-to-patient sales channel. Over 14,000 providers have prescribed the Fisher Wallace Stimulator®.
The company’s ongoing clinical research is designed to both obtain new FDA Approval and Clearances, as well as enable the company to expand insurance coverage. Medicaid in Maine (MaineCare) became the first state Medicaid program to fully cover the purchase of the Fisher Wallace device.
*OAK (Version 2) is currently under development and not yet available on the market.
WHY INVEST
Join us as we disrupt the mental health industry
*OAK (Version 2) is currently under development and not yet available on the market.
Our team is uniquely prepared to bring a refreshing vision of mental healthcare to life. We believe we possess the technology, skills, and timing required to successfully build and scale our solution. Become a shareholder in Fisher Wallace as we disrupt the status quo to better serve tens of millions of patients. Invest $1,500+ and receive a coupon code at the conclusion of the campaign to obtain our Version 2.0 device for free!
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE
CROWDCHECK VERIFIED REPORT CAN BE FOUND HERE.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
ABOUT
HEADQUARTERS
630 Flushing Avenue, Box 84
Brooklyn, NY 11206
WEBSITE
View Site
Fisher Wallace Labs makes wearable brain stimulation technology that is cleared by the FDA to treat depression, anxiety and insomnia. The company recently submitted the results of a pivotal clinical trial to the FDA to obtain FDA Approval for the treatment of Major Depressive Disorder and is on track to complete development of its Version 2.0 device, OAK, by Summer 2023.
TEAM
Kelly Roman
Co-Founder, CEO, and Director
Charles "Chip" Fisher
Co-Founder & Chairman & Director
Simon Webster
Board Member
Peter Rojas
Advisor
TERMS
Fisher Wallace Laboratories
Overview
PRICE PER SHARE
$10.67
DEADLINE
Feb 25, 2024
VALUATION
$100.28M
AMOUNT RAISED
$37,647.16
Breakdown
MIN INVESTMENT
$490.82
MAX INVESTMENT
$999,992.40
MIN NUMBER OF SHARES OFFERED
46
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Class B Common Stock
MAX NUMBER OF SHARES OFFERED
937,207
Maximum Number of Shares Offered subject to adjustment for bonus shares
Loyalty Bonus
Investors who have previously invested in the company receive 5% bonus shares of the company’s Common Stock.
Amount-Based Bonus
Tier 1 | $1,500+
Invest $1,500+ and receive a free Fisher Wallace Version 2 Device and 2% bonus shares.
Tier 2 | $5,000+
Invest $5,000+ and receive a free Fisher Wallace Version 2 Device and 5% bonus shares.
Tier 3 | $10,000+
Free Fisher Wallace Version 2 Device and 10% bonus shares.
Tier 4 | $25,000+
Invest $25,000+ and receive a free Fisher Wallace Version 2 Device, 15% bonus shares.
ALL UPDATES
03.03.23
Fisher Wallace Launches Reg A+ Offering!
Thanks to our previous crowdfunding, Fisher Wallace successfully completed and submitted the results of its pivotal depression study to the FDA to obtain approval for the treatment of Major Depressive Disorder. No wearable device has ever been approved to treat depression before, and we've launched our new campaign to preserve our first-mover status, build our first app, and finance the tooling and manufacturing process for OAK.
We've simultaneously begun conversations with venture capital firms to support our growth and will keep you apprised of any commitments on that front.
We believe that our technology should ultimately achieve smartphone-level ubiquity given the prevalence of depression, anxiety and insomnia, which impact more than half of the US population.
According to a recent survey, nearly half of our customers consider their Fisher Wallace device as important as their cell phone, and more than three quarters of our customers intend to use a Fisher Wallace device for the rest of their lives to maintain mental health and cognitive performance.
Thank you for considering becoming an early investor. Anyone who invests $1500+ in this campaign will receive a coupon code to obtain OAK for free as soon as it's released. We encourage you to watch our new campaign video to hear CEO Kelly Roman discuss the future of Fisher Wallace.
REWARDS
$1,500
Tier 1
Invest $1,500+ and receive a free Fisher Wallace Version 2 Device and 2% bonus shares.
$5,000
Tier 2
Invest $5,000+ and receive a free Fisher Wallace Version 2 Device and 5% bonus shares.
$10,000
Tier 3
Free Fisher Wallace Version 2 Device and 10% bonus shares.
$25,000
Tier 4
Invest $25,000+ and receive a free Fisher Wallace Version 2 Device, 15% bonus shares.
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
